CD25 regulatory T cells determine secondary but not primary remission in EAE: impact on long-term disease progression

Area of Science:

• Neuroimmunology
• Autoimmune diseases

Background:

• Multiple sclerosis (MS) involves relapses and remissions, but underlying cellular mechanisms remain unclear.
• Understanding the cells and processes driving MS progression is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the role of regulatory T cells (Tregs) and T lymphocytes in the central nervous system (CNS) during relapsing experimental autoimmune encephalomyelitis (R-EAE), an animal model for MS.
• To determine if Treg cell depletion impacts disease remission and progression in R-EAE.

Main Methods:

• Utilized the R-EAE animal model to study multiple sclerosis.
• Identified CD4+CD25+ Treg cells expressing Foxp3 and CTLA-4, and T lymphocytes expressing surface CTLA-4 within the CNS.
• Depleted Treg cells to assess their impact on disease remission and progression.

Main Results:

• Treg cells and CTLA-4 expressing T lymphocytes were found in the CNS during R-EAE.
• The first remission occurred even after Treg cell depletion, but subsequent remissions were abolished.
• Autoantigen rechallenge during the acute phase showed an amplified cytokine response despite an unaltered first remission.

Conclusions:

• The cellular composition within the CNS during the initial phase of MS significantly influences long-term disease trajectory.
• Treg cells play a critical role in mediating secondary remissions in this MS model.
• Early immune responses in MS may predict the severity and progression of the disease.